摘要
目的:观察阿瑞匹坦联合托烷司琼预防高致吐化疗药物引起的恶心呕吐的疗效及不良反应。方法:收集第四军医大学唐都医院2015年1~6月行AC方案化疗的乳腺癌女性患者86例,随机分为试验组A组(阿瑞匹坦+托烷司琼+地塞米松)及对照组B组(托烷司琼+地塞米松),每组各43例,比较两组药物对预防化疗所致恶心、呕吐的临床疗效、不良反应及对生活质量的影响。结果:试验组恶心有效率为88.3%,优于对照组的67.4%(P<0.05);试验组预防急性呕吐有效率为83.7%,优于对照组的65.1%(P<0.05);试验组预防延迟性呕吐有效率为79%,优于对照组的55.8%(P<0.05)。不良反应方面,2组比较无显著性差异(P>0.05)。结论:阿瑞匹坦联合托烷司琼注射液、地塞米松能够有效预防高致吐化疗药物引起的恶心呕吐,不良反应轻,值得推广。
Objective: To investigate the effect of Aprepitant combined with Tropisetronhydrochloride injection and dexamethasone in the prevention of nausea and vomiting caused by high vomiting chemotherapy regimen. Methods:From 2015 January to 2015 June,collected 86 women cases of breast cancer patients who received chemotherapy of AC regimen in the Department Oncology of Tangdu Hospital Affiliated to the Fourth Military Medical University,they were randomly divided into observation group( aprepitant + tropisetron + dexamethasone) and control group( tropisetron + dexamethasone),each group includes43 cases,compared the 2 groups' clinical efficacy of prevention of nausea,vomiting induced by chemotherapy,adverse reactions. Results: In observation group,the nausea control rate was 88.3%,which was better than the control group 67. 4%( P < 0. 05). In observation group acute vomiting preventing efficiency was 83. 7%,which was better than the control group 65. 1%( P < 0. 05). The preventing effective rate of delayed vomiting in the observation group was 79%,which was better than the control group 55. 8%( P < 0. 05). Adverse reactions revealed no significant differences between the 2 groups( P > 0. 05). Conclusion: Aprepitantcombined with Tropisetronhydrochloride injection and dexamethasone can effectively prevent nausea and vomiting caused by AC chemotherapy in breast cancer of women patients with mild adverse reactions,it can improve the quality of life of patients and worthy of use in clinic.
出处
《现代肿瘤医学》
CAS
2016年第12期1946-1948,共3页
Journal of Modern Oncology
关键词
阿瑞匹坦
托烷司琼
化疗
恶心
呕吐
Aprepitant
Tropisetron
chemotherapy
nausea
vomiting
